SlideShare a Scribd company logo
1 of 1
Download to read offline
Introduction
Methods
Abstract
Skeletal muscle possesses the ability to repair and regenerate following injury. The
inflammatory response is an essential component of muscle repair. At critical periods
following injury, macrophages switch from a pro-inflammatory (M1) to a regenerative
(M2) phenotype to aid in the repair. We hypothesize that Klotho, a protein expressed
by inflammatory cells within injured muscle, is an important mediator of macrophage
phenotype. Wild-type (WT) mice were compared to a Klotho deficient (KL.Hm)
strain. Following a sterile BaCl2 injury, muscles were analyzed at 7 and 21 days post
injury (PI). Antibodies to CD68 (M1 marker), CD163 (M2c marker), CD206 (M2a
marker) were used to evaluate macrophage phenotype. Following injury, ablation of
Klotho increased CD68+ cells 7 days PI and decreased CD163+ and CD206+ cells 21
days PI compared to WT. In addition to macrophage phenotype, we assayed for the
presence of eosinophils using anti-MBP-1 and regulatory T-cells using anti-FoxP3
because they are also leukocytes that can affect muscle regeneration. At 7 days PI,
MBP-1+ cells were down regulated in KL.Hm compared to WT. There were no
differences in FoxP3+ cells after injury. Our results reveal that Klotho deficiency
promotes a pro-inflammatory environment after muscle injury. Therefore, Klotho may
be an important mediator of muscle regeneration by affecting the inflammatory
response following injury.
Martina M. Shoukralla, Steven S. Welc, and James G. Tidball
Department of Integrative Biology and Physiology, University of California Los Angeles
Discussion and Conclusions
Klotho’s Effects on Skeletal Muscle’s Inflammatory Response During Muscle Regeneration
Results
•  Mouse Strains: heterozygous Klotho mice on C57BL/6 background were provided by Dr. M.
Kuro-o at the University of Texas Southwestern Medical Center as a gift.
•  BaCl2 sterile muscle injury: The left tibialis anterior (TA) was injected with 50 µl of a 1.2%
barium chloride (BaCl2) solution. The contralateral leg served as an uninjured control muscle.
Mice were sacrificed at 7 and 21 days post injury.
•  Immunohistochemistry: Rat αCD68 (1:100, Serotec) was used as a primary antibody for
labeling M1 macrophages and rabbit αCD163 (1:100, Santa Cruz), and rat αCD206 (1:50,
Serotec) were used as primary antibodies for identifying M2 macrophages. Anti-major basic
protein (αMBP-1) (1:3000) was used as a primary antibody to label eosinophils and αFoxP3
was used to label regulatory T cells.
1. Inflammation is an important step in skeletal muscle regeneration.
2. Following injury pro-inflammatory Th1 response takes place. This period is marked
by the infiltration of neutrophils and M1 macrophages.
3. The inflammatory phase resolves into a pro-regenerative Th2 phase several days
after injury. A switch in macrophage phenotype from M1 to M2 highlights this phase.
•  Klotho is an important protein for regulating the inflammatory environment after muscle
injury.
•  Klotho-deficient mice experienced an increase in M1 macrophages and a decrease in
eosinophils at 7 days PI.
•  The reduction in M2 macrophages in Klotho-deficient mice at 21 days PI suggests
impairment of the Th2 inflammatory response that is associated with muscle
regeneration.
•  Additional work is needed to determine if Klotho is a direct or indirect regulator of
macrophage phenotype.
•  Overall, our data support the possibility that Klotho has a significant role in regulation
muscle inflammation and repair following injury.
•  Tidball JG. Mechanisms of muscle injury, repair, and regeneration. Compr Physiol. 2011 Oct;
1(4):2029-62. doi: 10.1002/cphy.c100092. Review.
Figure 2: Regulatory T-cell abundance in KL.Hm vs. WT.
Non-injured, 7 days PI and 21 days PI TA muscles were analyzed for regulatory T-cell (T-
reg.) abundance. FoxP3 is a T-reg. marker. Data are presented as mean ± SEM. One-way
analysis of variance was used to test whether differences between groups were significant at
p < 0.05. Significant differences between groups were identified using Bonferroni's follow
up test. # vs. non-inj. of same genotype.
A.
B.
C.
Figure 1: The effect of Klotho on macrophage phenotype.
Non-injured, 7 days PI and 21 days PI TA muscles were analyzed for macrophage
phenotype.
Figures on the left: A. CD68 is M1 macrophage marker. B. CD163 is M2c macrophage
marker. C. CD206 is M2a macrophage marker. Data are presented as mean ± SEM. One-
way analysis of variance was used to test whether differences between groups were
significant at p < 0.05. Significant differences between groups were identified using
Tukey’s Post Hoc test. * vs. WT injured under same conditions. # vs. non-inj. of same
genotype. $ vs. 7-d P.I. of same genotype.
Figures on the right represent cross-sections of TA muscle at 7 days PI in KL.Hm vs.
WT mice. A. TA muscles immunolabeled with anti-CD68 to show M1 macrophages
(red). B. Anti-CD163 marker was used to show M2c macrophages (red). C. Anti-CD206
immunolabel was used to show M2a macrophages (red).
CD68
Non-inj 7d PI 21d PI
0
10000
20000
30000
cells/mm3
WT
KL.Hm
#
#
*
$
$
CD163
Non-inj 7d PI 21d PI
0
2000
4000
6000
cells/mm3
WT
KL.Hm
#
CD 206
Non-inj 7d PI 21d PI
0
5000
10000
15000
20000
cells/mm3
WT
KL.Hm
#
MBP
Non-inj 7d PI 21d PI
0
1000
2000
3000
4000
5000
cells/mm3
WT
KL.Hm
#
*
#
$
Figure 3: Eosinophil abundance in KL.Hm vs. WT.
A. Non-injured, 7 days PI and 21 days PI TA muscles were analyzed for eosinophil
abundance. MBP-1 is an eosinophil marker. Data are presented as mean ± SEM. One-way
analysis of variance was used to test whether differences between groups were significant at
p < 0.05. Significant differences between groups were identified using Tukey’s Post Hoc
test. * vs. WT injured under same conditions. # vs. non-inj. of same genotype. $ vs. 7-d P.I.
of same genotype. B. Cross-sections of TA muscle, at 7 days PI, immunolabled with anti-
MBP-1 to show eosinophils (red).
0
200
400
600
cells/m3
FoxP3, WT vs KL.Hm
Non-inj 7d PI 21d PI
#
WT KL.Hm
A.
B.
WT
KL.Hm
KL.Hm
WT
WT
KL.Hm

More Related Content

What's hot (20)

Extended Abstract
Extended AbstractExtended Abstract
Extended Abstract
 
CHORI Poster Final
CHORI Poster FinalCHORI Poster Final
CHORI Poster Final
 
Samuel Dugger FGF8b Final Report
Samuel Dugger FGF8b Final ReportSamuel Dugger FGF8b Final Report
Samuel Dugger FGF8b Final Report
 
BMES poster 2013
BMES poster 2013BMES poster 2013
BMES poster 2013
 
Hum. Mol. Genet.-2014-Goldstein-hmg-ddu390
Hum. Mol. Genet.-2014-Goldstein-hmg-ddu390Hum. Mol. Genet.-2014-Goldstein-hmg-ddu390
Hum. Mol. Genet.-2014-Goldstein-hmg-ddu390
 
Jsi 124 pathway
Jsi 124 pathwayJsi 124 pathway
Jsi 124 pathway
 
Marfia_et_al-2014-Glia
Marfia_et_al-2014-GliaMarfia_et_al-2014-Glia
Marfia_et_al-2014-Glia
 
New understanding mast cell function
New understanding mast cell functionNew understanding mast cell function
New understanding mast cell function
 
2016 Spring Poster
2016 Spring Poster 2016 Spring Poster
2016 Spring Poster
 
I M F D A
I M  F D AI M  F D A
I M F D A
 
Financial Benefits Of Immune Enhancement
Financial  Benefits Of  Immune  EnhancementFinancial  Benefits Of  Immune  Enhancement
Financial Benefits Of Immune Enhancement
 
Symposium Poster 2014
Symposium Poster 2014Symposium Poster 2014
Symposium Poster 2014
 
William Kay YIG 2
William Kay YIG 2William Kay YIG 2
William Kay YIG 2
 
Secreção de MCP-1 por fibroblastos
Secreção de MCP-1 por fibroblastosSecreção de MCP-1 por fibroblastos
Secreção de MCP-1 por fibroblastos
 
Biology of mast cells
Biology of mast cellsBiology of mast cells
Biology of mast cells
 
1-s2.0-S1063458416007354
1-s2.0-S10634584160073541-s2.0-S1063458416007354
1-s2.0-S1063458416007354
 
LaurenBrewerPoster_FinalDJM
LaurenBrewerPoster_FinalDJMLaurenBrewerPoster_FinalDJM
LaurenBrewerPoster_FinalDJM
 
art_10.1007_s00262-015-1719-z (2)
art_10.1007_s00262-015-1719-z (2)art_10.1007_s00262-015-1719-z (2)
art_10.1007_s00262-015-1719-z (2)
 
ncomms8821-최종본
ncomms8821-최종본ncomms8821-최종본
ncomms8821-최종본
 
Antimicrob. agents chemother. 1999-mingeot-leclercq-727-37
Antimicrob. agents chemother. 1999-mingeot-leclercq-727-37Antimicrob. agents chemother. 1999-mingeot-leclercq-727-37
Antimicrob. agents chemother. 1999-mingeot-leclercq-727-37
 

Similar to Martina.Shoukralla.May11 Poster

Satzer et al., 2015
Satzer et al., 2015Satzer et al., 2015
Satzer et al., 2015Jake Maxon
 
Endothelial Cell Mediated Delay of Blood Brain Barrier Recovery Following Tra...
Endothelial Cell Mediated Delay of Blood Brain Barrier Recovery Following Tra...Endothelial Cell Mediated Delay of Blood Brain Barrier Recovery Following Tra...
Endothelial Cell Mediated Delay of Blood Brain Barrier Recovery Following Tra...Arthur Stem
 
Koehne, G., et al. Galinpepimut-S in multiple myeloma data – clinical updates...
Koehne, G., et al. Galinpepimut-S in multiple myeloma data – clinical updates...Koehne, G., et al. Galinpepimut-S in multiple myeloma data – clinical updates...
Koehne, G., et al. Galinpepimut-S in multiple myeloma data – clinical updates...sellasq4
 
1-s2.0-S0006899315005375-main
1-s2.0-S0006899315005375-main1-s2.0-S0006899315005375-main
1-s2.0-S0006899315005375-mainAngela Xie
 
Mesenchymal stem cell therapy
Mesenchymal stem cell therapyMesenchymal stem cell therapy
Mesenchymal stem cell therapySpringer
 
Basics of cancer immunotherapy 2017
Basics of cancer immunotherapy 2017Basics of cancer immunotherapy 2017
Basics of cancer immunotherapy 2017Emad Shash
 
Nutrição e Inflamação, Maio, 2013
Nutrição e Inflamação, Maio, 2013Nutrição e Inflamação, Maio, 2013
Nutrição e Inflamação, Maio, 2013Pedro Bastos
 
Cellular Therapy for multiple myeloma
Cellular Therapy for multiple myelomaCellular Therapy for multiple myeloma
Cellular Therapy for multiple myelomaspa718
 
NANCY SUNNYBROOK POSTER PRINT-1
NANCY SUNNYBROOK POSTER PRINT-1NANCY SUNNYBROOK POSTER PRINT-1
NANCY SUNNYBROOK POSTER PRINT-1Nancy Yu
 
From syngenic to_humanised_models_mirjolet_oncodesign
From syngenic to_humanised_models_mirjolet_oncodesignFrom syngenic to_humanised_models_mirjolet_oncodesign
From syngenic to_humanised_models_mirjolet_oncodesignFlorence Fombertasse
 
Life Science Journal 2012;9(2s).PDF
Life Science Journal 2012;9(2s).PDFLife Science Journal 2012;9(2s).PDF
Life Science Journal 2012;9(2s).PDFnashwa eltablawy
 
2016_Association for Research in Vision and Ophthalmology_2
2016_Association for Research in Vision and Ophthalmology_22016_Association for Research in Vision and Ophthalmology_2
2016_Association for Research in Vision and Ophthalmology_2Mauricio Rosenfeld
 
Aberrant muscle antigen exposure in mice is sufficient to cause myositis in a...
Aberrant muscle antigen exposure in mice is sufficient to cause myositis in a...Aberrant muscle antigen exposure in mice is sufficient to cause myositis in a...
Aberrant muscle antigen exposure in mice is sufficient to cause myositis in a...Nicholas Young
 
Sliver nanoparticles accelerate skin wound healing in mice (Mus musculus) thr...
Sliver nanoparticles accelerate skin wound healing in mice (Mus musculus) thr...Sliver nanoparticles accelerate skin wound healing in mice (Mus musculus) thr...
Sliver nanoparticles accelerate skin wound healing in mice (Mus musculus) thr...Nanomedicine Journal (NMJ)
 
Immunotherapy advances in lung cancer
Immunotherapy advances in lung cancerImmunotherapy advances in lung cancer
Immunotherapy advances in lung cancerAlok Gupta
 
Identification of personalized therapies for LKB1 Mutant lung cancer using a ...
Identification of personalized therapies for LKB1 Mutant lung cancer using a ...Identification of personalized therapies for LKB1 Mutant lung cancer using a ...
Identification of personalized therapies for LKB1 Mutant lung cancer using a ...Alex Yang
 

Similar to Martina.Shoukralla.May11 Poster (20)

Satzer et al., 2015
Satzer et al., 2015Satzer et al., 2015
Satzer et al., 2015
 
Endothelial Cell Mediated Delay of Blood Brain Barrier Recovery Following Tra...
Endothelial Cell Mediated Delay of Blood Brain Barrier Recovery Following Tra...Endothelial Cell Mediated Delay of Blood Brain Barrier Recovery Following Tra...
Endothelial Cell Mediated Delay of Blood Brain Barrier Recovery Following Tra...
 
Koehne, G., et al. Galinpepimut-S in multiple myeloma data – clinical updates...
Koehne, G., et al. Galinpepimut-S in multiple myeloma data – clinical updates...Koehne, G., et al. Galinpepimut-S in multiple myeloma data – clinical updates...
Koehne, G., et al. Galinpepimut-S in multiple myeloma data – clinical updates...
 
1-s2.0-S0006899315005375-main
1-s2.0-S0006899315005375-main1-s2.0-S0006899315005375-main
1-s2.0-S0006899315005375-main
 
Mesenchymal stem cell therapy
Mesenchymal stem cell therapyMesenchymal stem cell therapy
Mesenchymal stem cell therapy
 
Basics of cancer immunotherapy 2017
Basics of cancer immunotherapy 2017Basics of cancer immunotherapy 2017
Basics of cancer immunotherapy 2017
 
Nutrição e Inflamação, Maio, 2013
Nutrição e Inflamação, Maio, 2013Nutrição e Inflamação, Maio, 2013
Nutrição e Inflamação, Maio, 2013
 
Cellular Therapy for multiple myeloma
Cellular Therapy for multiple myelomaCellular Therapy for multiple myeloma
Cellular Therapy for multiple myeloma
 
NANCY SUNNYBROOK POSTER PRINT-1
NANCY SUNNYBROOK POSTER PRINT-1NANCY SUNNYBROOK POSTER PRINT-1
NANCY SUNNYBROOK POSTER PRINT-1
 
From syngenic to_humanised_models_mirjolet_oncodesign
From syngenic to_humanised_models_mirjolet_oncodesignFrom syngenic to_humanised_models_mirjolet_oncodesign
From syngenic to_humanised_models_mirjolet_oncodesign
 
In press
In pressIn press
In press
 
Lessons from Psoriasis: What Can We Apply to Alopecia Areata?
Lessons from Psoriasis: What Can We Apply to Alopecia Areata?Lessons from Psoriasis: What Can We Apply to Alopecia Areata?
Lessons from Psoriasis: What Can We Apply to Alopecia Areata?
 
Life Science Journal 2012;9(2s).PDF
Life Science Journal 2012;9(2s).PDFLife Science Journal 2012;9(2s).PDF
Life Science Journal 2012;9(2s).PDF
 
2016_Association for Research in Vision and Ophthalmology_2
2016_Association for Research in Vision and Ophthalmology_22016_Association for Research in Vision and Ophthalmology_2
2016_Association for Research in Vision and Ophthalmology_2
 
Bethea, John
Bethea, JohnBethea, John
Bethea, John
 
Aberrant muscle antigen exposure in mice is sufficient to cause myositis in a...
Aberrant muscle antigen exposure in mice is sufficient to cause myositis in a...Aberrant muscle antigen exposure in mice is sufficient to cause myositis in a...
Aberrant muscle antigen exposure in mice is sufficient to cause myositis in a...
 
Sliver nanoparticles accelerate skin wound healing in mice (Mus musculus) thr...
Sliver nanoparticles accelerate skin wound healing in mice (Mus musculus) thr...Sliver nanoparticles accelerate skin wound healing in mice (Mus musculus) thr...
Sliver nanoparticles accelerate skin wound healing in mice (Mus musculus) thr...
 
Immunotherapy advances in lung cancer
Immunotherapy advances in lung cancerImmunotherapy advances in lung cancer
Immunotherapy advances in lung cancer
 
Identification of personalized therapies for LKB1 Mutant lung cancer using a ...
Identification of personalized therapies for LKB1 Mutant lung cancer using a ...Identification of personalized therapies for LKB1 Mutant lung cancer using a ...
Identification of personalized therapies for LKB1 Mutant lung cancer using a ...
 
AOCPMR poster final
AOCPMR poster finalAOCPMR poster final
AOCPMR poster final
 

Martina.Shoukralla.May11 Poster

  • 1. Introduction Methods Abstract Skeletal muscle possesses the ability to repair and regenerate following injury. The inflammatory response is an essential component of muscle repair. At critical periods following injury, macrophages switch from a pro-inflammatory (M1) to a regenerative (M2) phenotype to aid in the repair. We hypothesize that Klotho, a protein expressed by inflammatory cells within injured muscle, is an important mediator of macrophage phenotype. Wild-type (WT) mice were compared to a Klotho deficient (KL.Hm) strain. Following a sterile BaCl2 injury, muscles were analyzed at 7 and 21 days post injury (PI). Antibodies to CD68 (M1 marker), CD163 (M2c marker), CD206 (M2a marker) were used to evaluate macrophage phenotype. Following injury, ablation of Klotho increased CD68+ cells 7 days PI and decreased CD163+ and CD206+ cells 21 days PI compared to WT. In addition to macrophage phenotype, we assayed for the presence of eosinophils using anti-MBP-1 and regulatory T-cells using anti-FoxP3 because they are also leukocytes that can affect muscle regeneration. At 7 days PI, MBP-1+ cells were down regulated in KL.Hm compared to WT. There were no differences in FoxP3+ cells after injury. Our results reveal that Klotho deficiency promotes a pro-inflammatory environment after muscle injury. Therefore, Klotho may be an important mediator of muscle regeneration by affecting the inflammatory response following injury. Martina M. Shoukralla, Steven S. Welc, and James G. Tidball Department of Integrative Biology and Physiology, University of California Los Angeles Discussion and Conclusions Klotho’s Effects on Skeletal Muscle’s Inflammatory Response During Muscle Regeneration Results •  Mouse Strains: heterozygous Klotho mice on C57BL/6 background were provided by Dr. M. Kuro-o at the University of Texas Southwestern Medical Center as a gift. •  BaCl2 sterile muscle injury: The left tibialis anterior (TA) was injected with 50 µl of a 1.2% barium chloride (BaCl2) solution. The contralateral leg served as an uninjured control muscle. Mice were sacrificed at 7 and 21 days post injury. •  Immunohistochemistry: Rat αCD68 (1:100, Serotec) was used as a primary antibody for labeling M1 macrophages and rabbit αCD163 (1:100, Santa Cruz), and rat αCD206 (1:50, Serotec) were used as primary antibodies for identifying M2 macrophages. Anti-major basic protein (αMBP-1) (1:3000) was used as a primary antibody to label eosinophils and αFoxP3 was used to label regulatory T cells. 1. Inflammation is an important step in skeletal muscle regeneration. 2. Following injury pro-inflammatory Th1 response takes place. This period is marked by the infiltration of neutrophils and M1 macrophages. 3. The inflammatory phase resolves into a pro-regenerative Th2 phase several days after injury. A switch in macrophage phenotype from M1 to M2 highlights this phase. •  Klotho is an important protein for regulating the inflammatory environment after muscle injury. •  Klotho-deficient mice experienced an increase in M1 macrophages and a decrease in eosinophils at 7 days PI. •  The reduction in M2 macrophages in Klotho-deficient mice at 21 days PI suggests impairment of the Th2 inflammatory response that is associated with muscle regeneration. •  Additional work is needed to determine if Klotho is a direct or indirect regulator of macrophage phenotype. •  Overall, our data support the possibility that Klotho has a significant role in regulation muscle inflammation and repair following injury. •  Tidball JG. Mechanisms of muscle injury, repair, and regeneration. Compr Physiol. 2011 Oct; 1(4):2029-62. doi: 10.1002/cphy.c100092. Review. Figure 2: Regulatory T-cell abundance in KL.Hm vs. WT. Non-injured, 7 days PI and 21 days PI TA muscles were analyzed for regulatory T-cell (T- reg.) abundance. FoxP3 is a T-reg. marker. Data are presented as mean ± SEM. One-way analysis of variance was used to test whether differences between groups were significant at p < 0.05. Significant differences between groups were identified using Bonferroni's follow up test. # vs. non-inj. of same genotype. A. B. C. Figure 1: The effect of Klotho on macrophage phenotype. Non-injured, 7 days PI and 21 days PI TA muscles were analyzed for macrophage phenotype. Figures on the left: A. CD68 is M1 macrophage marker. B. CD163 is M2c macrophage marker. C. CD206 is M2a macrophage marker. Data are presented as mean ± SEM. One- way analysis of variance was used to test whether differences between groups were significant at p < 0.05. Significant differences between groups were identified using Tukey’s Post Hoc test. * vs. WT injured under same conditions. # vs. non-inj. of same genotype. $ vs. 7-d P.I. of same genotype. Figures on the right represent cross-sections of TA muscle at 7 days PI in KL.Hm vs. WT mice. A. TA muscles immunolabeled with anti-CD68 to show M1 macrophages (red). B. Anti-CD163 marker was used to show M2c macrophages (red). C. Anti-CD206 immunolabel was used to show M2a macrophages (red). CD68 Non-inj 7d PI 21d PI 0 10000 20000 30000 cells/mm3 WT KL.Hm # # * $ $ CD163 Non-inj 7d PI 21d PI 0 2000 4000 6000 cells/mm3 WT KL.Hm # CD 206 Non-inj 7d PI 21d PI 0 5000 10000 15000 20000 cells/mm3 WT KL.Hm # MBP Non-inj 7d PI 21d PI 0 1000 2000 3000 4000 5000 cells/mm3 WT KL.Hm # * # $ Figure 3: Eosinophil abundance in KL.Hm vs. WT. A. Non-injured, 7 days PI and 21 days PI TA muscles were analyzed for eosinophil abundance. MBP-1 is an eosinophil marker. Data are presented as mean ± SEM. One-way analysis of variance was used to test whether differences between groups were significant at p < 0.05. Significant differences between groups were identified using Tukey’s Post Hoc test. * vs. WT injured under same conditions. # vs. non-inj. of same genotype. $ vs. 7-d P.I. of same genotype. B. Cross-sections of TA muscle, at 7 days PI, immunolabled with anti- MBP-1 to show eosinophils (red). 0 200 400 600 cells/m3 FoxP3, WT vs KL.Hm Non-inj 7d PI 21d PI # WT KL.Hm A. B. WT KL.Hm KL.Hm WT WT KL.Hm